Search results
Showing 301 to 350 of 2048 results for work
Read biographies of the members of our quality standards advisory committee.
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Help us improve Help...
a stakeholder People and communities - putting you at the heart of our work Help develop quality standards Help us improve Help...
Awaiting development Reference number: GID-TA11308 Expected publication date: TBC
In development Reference number: GID-QS10094 Expected publication date: 01 July 2026
A range of resources to help healthcare professionals effectively apply NICE guidance to enhance patient care and streamline clinical practices.
This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.
Low back pain and sciatica in over 16s: assessment and management (NG59)
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)
Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.
How providers and commissioners can use quality standards to improve the quality of care
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
Read biographies for all members of NICE's indicator advisory committee.
Read biographies for all members of NICE's indicator advisory committee.
Read NICE's statement on modern slavery and human trafficking.
Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.
View quality statements for QS72Show all sections
Sections for QS72
- Quality statements
- Quality statement 1: Education programmes
- Quality statement 2: Transplantation – pre-emptive
- Quality statement 3: Transplantation – on dialysis
- Quality statement 4: Dialysis access preparation
- Quality statement 5: Home-based dialysis
- Quality statement 6: Patient transport
- Quality statement 7: Transplantation – rapid access to a specialist histopathology service
Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.
Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.
Prosthetic intervertebral disc replacement in the lumbar spine (HTG197)
Evidence-based recommendations on prosthetic intervertebral disc replacement in the lumbar spine. This involves removing the damaged disc and inserting an artificial disc in its place.
View recommendations for HTG197Show all sections
Sections for HTG197
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]
In development Reference number: GID-TA11445 Expected publication date: TBC
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Outside interests of the NICE board
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
Workplace health: long-term sickness absence and incapacity to work (PH19)
This guideline has been updated and replaced by NICE guideline NG146.
This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.
View recommendations for CG138Show all sections
This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development Reference number: GID-HST10062 Expected publication date: 17 March 2027
The key stages in development of our quality standards
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.
This document contains advice to help you access treatments and care that NICE has recommended
Depression in children and young people: identification and management (NG134)
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]
Awaiting development Reference number: GID-TA11530 Expected publication date: TBC
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.
Antisocial personality disorder: prevention and management (CG77)
This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.